|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase/hydrolase inhibitor
|
 |
|
Title:
|
 |
Crystal structures of caspase-3 in complex with aza-peptide michael acceptor inhibitors.
|
|
Structure:
|
 |
Caspase-3 subunit p17. Chain: a. Fragment: alpha subunit, residues 29-175. Synonym: casp-3, apopain, cysteine protease cpp32, yama protein, cpp- 32, srebp cleavage activity 1, sca-1. Engineered: yes. Caspase-3 subunit p12. Chain: b. Fragment: beta subunit, residues 176-277.
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 469008. Synthetic: yes. Synthetic construct. Organism_taxid: 32630
|
|
Biol. unit:
|
 |
Hexamer (from PDB file)
|
|
Resolution:
|
 |
|
1.77Å
|
R-factor:
|
0.163
|
R-free:
|
0.188
|
|
|
Authors:
|
 |
M.G.Grutter
|
|
Key ref:
|
 |
O.D.Ekici
et al.
(2006).
Design, synthesis, and evaluation of aza-peptide Michael acceptors as selective and potent inhibitors of caspases-2, -3, -6, -7, -8, -9, and -10.
J Med Chem,
49,
5728-5749.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
14-Sep-05
|
Release date:
|
20-Sep-06
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Med Chem
49:5728-5749
(2006)
|
|
PubMed id:
|
|
|
|
|
| |
|
Design, synthesis, and evaluation of aza-peptide Michael acceptors as selective and potent inhibitors of caspases-2, -3, -6, -7, -8, -9, and -10.
|
|
O.D.Ekici,
Z.Z.Li,
A.J.Campbell,
K.E.James,
J.L.Asgian,
J.Mikolajczyk,
G.S.Salvesen,
R.Ganesan,
S.Jelakovic,
M.G.Grütter,
J.C.Powers.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Aza-peptide Michael acceptors are a novel class of inhibitors that are potent
and specific for caspases-2, -3, -6, -7, -8, -9, and -10. The second-order rate
constants are in the order of 10(6) M(-1) s(-1). The aza-peptide Michael
acceptor inhibitor 18t (Cbz-Asp-Glu-Val-AAsp-trans-CH=CH-CON(CH(2)-1-Naphth)(2)
is the most potent compound and it inhibits caspase-3 with a k(2) value of
5620000 M(-1) s(-1). The inhibitor 18t is 13700, 190, 6.4, 594, 37500, and
173-fold more selective for caspase-3 over caspases-2, -6, -7, -8, -9, and -10,
respectively. Aza-peptide Michael acceptors designed with caspase specific
sequences are selective and do not show any cross reactivity with clan CA
cysteine proteases such as papain, cathepsin B, and calpains. High-resolution
crystal structures of caspase-3 and caspase-8 in complex with aza-peptide
Michael acceptor inhibitors demonstrate the nucleophilic attack on C2 and
provide insight into the selectivity and potency of the inhibitors with respect
to the P1' moiety.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
M.J.Leyva,
F.Degiacomo,
L.S.Kaltenbach,
J.Holcomb,
N.Zhang,
J.Gafni,
H.Park,
D.C.Lo,
G.S.Salvesen,
L.M.Ellerby,
and
J.A.Ellman
(2010).
Identification and evaluation of small molecule pan-caspase inhibitors in Huntington's disease models.
|
| |
Chem Biol,
17,
1189-1200.
|
 |
|
|
|
|
 |
S.Amslinger
(2010).
The tunable functionality of alpha,beta-unsaturated carbonyl compounds enables their differential application in biological systems.
|
| |
ChemMedChem,
5,
351-356.
|
 |
|
|
|
|
 |
H.J.Kang,
Y.M.Lee,
Y.J.Jeong,
K.Park,
M.Jang,
S.G.Park,
K.H.Bae,
M.Kim,
and
S.J.Chung
(2008).
Large-scale preparation of active caspase-3 in E. coli by designing its thrombin-activatable precursors.
|
| |
BMC Biotechnol,
8,
92.
|
 |
|
|
|
|
 |
K.S.Babu,
X.C.Li,
M.R.Jacob,
Q.Zhang,
S.I.Khan,
D.Ferreira,
and
A.M.Clark
(2006).
Synthesis, antifungal activity, and structure-activity relationships of coruscanone A analogues.
|
| |
J Med Chem,
49,
7877-7886.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
');
}
}
 |